Business Wire
-
October 16, 2026
Fujifilm’s instax mini Evo Cinema™ Named One of TIME’s Best Inventions of 2026
Oct. 15, 2026 15:39 UTC Fujifilm’s instax mini Evo Cinema™ Named One of TIME’s Best Inventions of 2026 VALHALLA, N.Y.–(BUSINESS WIRE)– FUJIFILM North America Corporation announced today the instax mini Evo Cinema™ hybrid instant camera has been selected as one of TIME’s Best Inventions of 2026 in the Consumer Electronics category. This is the second consecutive year Fujifilm has been named to TIME’s Best Inventions list, with the instax WIDE Evo™ hybrid instant camera selected in 2025. Earlier this year, Fujifilm was recognized as a TIME100 Most Influential Company and named an industry leader in the hardware sector. “At Fujifilm, our whole purpose is centered around giving our world more […]
-

October 16, 2026
Xsolla and Game8.co Turn Game Guides Into Storefronts, Connecting Players and Publishers to the Global Market
Oct. 15, 2026 15:38 UTC Xsolla and Game8.co Turn Game Guides Into Storefronts, Connecting Players and Publishers to the Global Market Web Shop Links Inside Game8.Co, The English-Language Edition Of Game8, Japan’s Largest Game-Strategy Wiki, Brings Direct-To-Consumer Purchasing To The Moment Of Player Intent And Opens A Bridge For Publishers LOS ANGELES–(BUSINESS WIRE)– Xsolla, a global commerce company, today announced a partnership with Game8.co, Japan’s largest video game strategy wiki, that places Xsolla-powered web shop links directly in Game8.co’s guides. Players reading a walkthrough can go straight to a publisher’s direct-to-consumer storefront when they decide to spend, and Game8.co receives a share of the revenue its guides generate. This press […]
-

October 16, 2026
Body of Waves, a New Artwork Only at teamLab Planets TOKYO, Unveiled
Oct. 15, 2026 15:00 UTC Body of Waves, a New Artwork Only at teamLab Planets TOKYO, Unveiled The visitor experiences offered by “Existence in the Flow Creates Vortices” and “Waterfall of Ephemeral Crystals” have also been further expanded. TOKYO–(BUSINESS WIRE)– teamLab Planets TOKYO (hereinafter referred to as “teamLab Planets”) has unveiled Body of Waves, a new artwork in which visitors enter a soft sculpture with their entire bodies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014474897/en/ teamLab, Body of Waves, 2026, from the series Soft Black Hole – Your Body Becomes a Space that Influences Another Body, 2016-© teamLab *Shot in real space. No AI or CGI. […]
-

October 16, 2026
NOHGA SHINJUKU GYOEN National Garden – a Lifestyle Hotel Offering Views of Shinjuku Gyoen National Garden from Every Room Scheduled to Open on July 15, 2027. Reservations Begin on October 15, 2026
Oct. 15, 2026 15:00 UTC NOHGA SHINJUKU GYOEN National Garden – a Lifestyle Hotel Offering Views of Shinjuku Gyoen National Garden from Every Room Scheduled to Open on July 15, 2027. Reservations Begin on October 15, 2026 Offering a unique stay experience where the vibrancy of the city and the natural beauty of Shinjuku Gyoen National Garden come together. TOKYO–(BUSINESS WIRE)– Nomura Real Estate Hotels Co., Ltd.: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015296952/en/ The balcony overlooking Shinjuku Gyoen National Garden Key points in this release 1. The fourth property of the NOHGA HOTEL, a lifestyle hotel brand, will open on Thursday, July 15, 2027. 2. […]
-
October 15, 2026
I Squared Capital Opens Tokyo Office, Deepening Commitment to Japan
Oct. 15, 2026 07:00 UTC I Squared Capital Opens Tokyo Office, Deepening Commitment to Japan New Tokyo office builds on more than a decade of investment across Asia-Pacific and over US$9 billion deployed in the region TOKYO & MIAMI–(BUSINESS WIRE)–I Squared Capital (“I Squared”), a leading independent global infrastructure investor with US $60 billion in assets under management, today announced the opening of its Tokyo office, further strengthening the firm’s presence in one of Asia-Pacific’s most important infrastructure markets. The expansion reflects I Squared’s long-term conviction in Japan, where significant infrastructure investment needs and the country’s energy and digital transformation are driving demand for private capital and specialist expertise. The […]
-
October 15, 2026
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Oct. 15, 2026 00:30 UTC Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 − ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following […]
-
October 15, 2026
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
Oct. 14, 2026 17:43 UTC JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome – This approval follows the recent marketing authorization for IZCARGO™ in the United Arab Emirates – HYOGO, Japan–(BUSINESS WIRE)– JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that IZCARGO™ (pabinafusp alfa, or JR-141), a blood-brain barrier-penetrating enzyme replacement therapy (ERT) for Hunter syndrome developed using JCR’s proprietary J-Brain Cargo® technology, received conditional marketing authorization in Kuwait. Kuwait is the second market outside Japan where IZCARGO™ has received approval, following the United Arab […]
-

October 14, 2026
eM Client 11 Launches Across Asia: AI-Powered Outlook Alternative Combining Advanced Productivity, Flexibility, and Competitive Pricing
Oct. 14, 2026 13:31 UTC eM Client 11 Launches Across Asia: AI-Powered Outlook Alternative Combining Advanced Productivity, Flexibility, and Competitive Pricing PRAGUE–(BUSINESS WIRE)– eM Client, the European developer of an email and productivity application used by millions worldwide, today announced eM Client 11, its most significant release to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014613633/en/ eM Client 11 main window Combining advanced AI capabilities, intelligent automation, and competitive pricing, eM Client 11 offers professionals and businesses across Asia a powerful, cost-effective alternative to Microsoft Outlook, with greater flexibility and control over their email experience. Smarter Email with AI eM Client 11 introduces an integrated AI […]
-

October 14, 2026
Lenovo Uncovers What Happens When Entrepreneurs Look Beyond Borders for Support
Oct. 14, 2026 13:00 UTC Lenovo Uncovers What Happens When Entrepreneurs Look Beyond Borders for Support New documentary series follows small business founders from around the world as unexpected connections and technology spark fresh ideas, new approaches to business challenges and opportunities for growth MORRISVILLE, N.C.–(BUSINESS WIRE)– Today, Lenovo debuts the first episode of its new documentary series from Backing Every Business, its global initiative designed to connect small businesses with the people, technology and support they need to grow and thrive. The series features five businesses participating in Twinning, Lenovo’s program that brings small business founders from around the world together, connecting them through mentorship across shared growth goals, […]
-
October 14, 2026
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Oct. 14, 2026 12:00 UTC Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 − TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE […]